|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Treatment with hyperbaric oxygen affects endothelial cell fibrinolysis 显示文摘 | Tjarnstrom J Holmdahl L Armell P | 1999 | Eur J Surg1999，，： | 1 |
| 2 | Optical properties of InSb layers confined by InP显示文摘 | Utzmeier T Armelles G Postigo P A | 1997 | Phys Rev1997，56，3： | 1 |
| 3 | Trifloxysulfuron Plus Pyrithiobac Mixtures for Broadleaf Weed Control in Cotton(Gossypium hirsutum)显示文摘 | RICHARDSON R J WILSON H P ARMEL G R | 2006 | Weed Technology2006，20，： | 1 |
| 4 | Influence of Adjuvants on Cotton(Gossypium hirsutum) Response to Postemergence Applications of CGA 3626221 显示文摘 | RICHARDSON R J WILSON H P ARMEL G R | 2004 | Weed Technology2004，18，： | 1 |
| 5 | Combination of nitroxide-mediated polymerization and SET-LRP for the synthesis of high molar mass branched and star-branched poly(nbutyl acrylate) characterized by size exclusion chromatography and rheology显示文摘 | SABRINA P ARMELLE R GERALD C | 2012 | Journal of Polymer Science Part A:Polymer Chemistry2012，50，14： | 1 |
| 6 | Raman scattering of InSb quantum dots grown on InP substrates显示文摘 | ARMELLES G UTZMEIER T POSTIGO P A | 1997 | Journal of Applied Physics1997，81，9： | 1 |
| 7 | Mesotrione alone and in mixtures with glyphosate in glyphosate resistant corn (Zea mays ) 显示文摘 | Armel G R Wilson H P Richardson R J | 2003 | Weed Technology2003，17，2： | 1 |
| 8 | Comparison of Mesotrione Combinations with Standard Weed Control Programs in Corn显示文摘 | Whaley C M Armel G R Wilson H P | 2006 | Weed Tech2006，20，： | 1 |
| 9 | Mesotrione, aceto- chlor, and atrazine for weed management in corn (Zea mays ) 显示文摘 | Armel G R Wilson H P Richardson R J | 2003 | Weed Technology2003，17，2： | 1 |
| 10 | Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib:Multicenter French clinical experience in real-life after matching显示文摘BACKGROUND Starting a second-line systemic treatment for hepatocellular carcinoma(HCC)is a common situation.The only therapeutic options in France are two broadspectrum tyrosine kinase inhibitors(TKIs),regorafenib(REG)and cabozantinib(CBZ),but no comparative real-life studies are available.AIM To evaluate the progression-free survival(PFS)of patients treated with REG or CBZ,we investigated the disease control rate(DCR),overall survival(OS),and safety of both drugs.To identify the variables associated with disease progression over time.METHODS A retrospective multicenter study was performed on the clinical data of patients attending one of three referral centers(Avignon,Marseille,and Nice)between January 2017 and March 2021 using propensity score matching.PFS and OS were assessed using the Kaplan-Meier method.Multivariate analysis(MA)of progression risk factors over time was performed in matched-pair groups.RESULTS Fifty-eight patients 68(62-74)years old with HCC,Barcelona clinic liver cancer(BCLC)B/C(86%),Child-Pugh(CP)-A/B(24%)received REG for 3.4(1.4-10.5)mo as second-line therapy.Twentyeight patients 68(60-73)years,BCLC B/C(75%),CP-A/B(25%)received CBZ for 3.7(1.8-4.9)mo after first-line treatment with sorafenib[3(2-4)(CBZ)vs 4(2.9-11.8)mo(REG),P=0.0226].Twenty percent of patients received third-line therapy.After matching,PFS and DCR were not significantly different after a median follow-up of 6.2(2.7-11.7)mo(REG)vs 5.2(4-7.2)mo(CBZ),P=0.6925.There was no difference in grade 3/4 toxicities,dose reductions,or interruptions.The OS of CP-A patients was 8.3(5.2-24.8)vs 4.9(1.6-11.7)mo(CP-B),P=0.0468.The MA of risk factors for progression over time identified C-reactive protein(CRP)>10 mg/L,neutrophil-to-lymphocyte ratio(NLR)>3,and aspartate aminotransferase(AST)>45 IU as predictive factors.CONCLUSION This multicenter indirect comparative study found no significant difference in PFS between REG and CBZ as second-line therapy for advanced HCC.Elevated levels of inflammatory markers(CRP and NLR)and AST were associated with non-control of TKIs over time.A 2-mo online progression risk calculation is proposed. | Xavier Adhoute Marie De Matharel Laurent Mineur Guillaume Pénaranda Dann Ouizeman Clemence Toullec Albert Tran Paul Castellani Armelle Rollet Valérie Oules HervéPerrier Si Nafa Si Ahmed Marc Bourliere Rodolphe Anty | 2022 | World Journal of Gastrointestinal Oncology2022，14，8： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员